HOUSE_OVERSIGHT_025891.jpg
2.95 MB
Extraction Summary
0
People
9
Organizations
4
Locations
2
Events
1
Relationships
3
Quotes
Document Information
Type:
Press release / investor relations announcement
File Size:
2.95 MB
Summary
This document is a press release or investor relations update from Sanofi and Regeneron dated around July 2015, detailing clinical trial results, pricing, and regulatory milestones for the cholesterol drug Praluent. It announces a positive opinion from the European Medicine Agency and schedules an investor conference call for July 24, 2015. The document bears a 'HOUSE_OVERSIGHT' footer, suggesting it was part of a document production to Congress, likely related to pharmaceutical pricing or regulatory investigations, though it contains no direct mentions of Jeffrey Epstein or his associates in this specific page.
Organizations (9)
Timeline (2 events)
2015-09-01
Expected final decision by European Commission on Marketing Authorization Application
European Union
Locations (4)
| Location | Context |
|---|---|
Key Quotes (3)
"The U.S. WAC price of Praluent is $40 per day ($1,120 every 28 days) for both the 75 mg and 150 mg doses"Source
HOUSE_OVERSIGHT_025891.jpg
Quote #1
"Sanofi and Regeneron are committed to ensuring that patients in the U.S. who are prescribed Praluent are able to access the medicine"Source
HOUSE_OVERSIGHT_025891.jpg
Quote #2
"Earlier today, the companies announced that the European Medicine Agency's (EMA's) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for the marketing authorization of Praluent"Source
HOUSE_OVERSIGHT_025891.jpg
Quote #3
Discussion 0
No comments yet
Be the first to share your thoughts on this epstein document